Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
about
Differential oestrogen receptor binding is associated with clinical outcome in breast cancerCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesMethylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathwaysRKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast CancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcomeERbeta in breast cancer--onlooker, passive player, or active protector?Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence dataModularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data setGenomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth.Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients.Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeFractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapyEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMinimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER statusEGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancerNuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.Progesterone receptor action: defining a role in breast cancerProgesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastasesClassical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapyAnalysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis.Stratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor lossEpidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancerA steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo.Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsAssociation of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.
P2860
Q24595511-6FE51AB1-D5A9-4767-B742-5B24FAD5708EQ26743510-77CE7209-D94C-4AE1-BA01-0409B034C25CQ27306870-30D92AAA-E31B-47EC-BC0E-2BA65A4632C1Q27670969-1A360AA3-BCBE-4EDC-96AB-B3CAB860336FQ28072897-A7C1413F-309A-47BD-89B4-DBA663425DA5Q28084982-C70ABF5E-885A-4BC8-A3D0-54A8ECB159DAQ28297992-58EC1E29-F98B-4F08-8D5D-7BD04F96B201Q30438399-5F91D8F7-18D2-4C21-83F0-8FD1D0C7C758Q30823432-C3D8F4B7-3771-4CC5-9B3E-D4CBF384BA25Q31014656-105C6DB3-790E-4A45-9BDB-781CE5CAC0CDQ31031200-00A1B806-9924-4915-ADCC-F69DE6FB468CQ31142731-3D8F40D4-BEDA-4B96-8F2C-F7837E98E6D5Q33239655-84FAF9EA-7CDE-4A6D-ADB8-49446F7B5E5AQ33266857-1E31692C-9D59-44DD-BB14-6598065BEEE9Q33496645-27072768-E024-4E4E-A582-A1900AE6AB25Q33506542-1F93696B-77F6-4BB3-8FB0-3C478EB5AE17Q33561588-4AEFBC3F-F8AF-4FCF-B3C5-6E2AA5CA16FFQ33568902-BC63A662-8509-4CD6-B473-F9C9EF9217F7Q33691211-6894A1ED-4F89-4D7F-AB9B-E7DC1FF4AFD2Q33769803-BC8BC6E8-5801-4EE0-A43B-8056F36FA17AQ33793142-D05EF66F-860C-4294-9D9B-82E5F5088F80Q33801131-98695948-0705-4981-B8BB-D69EEDF06934Q33939890-0CDEE96A-8F11-4565-AD69-88B8A8CD863CQ33998721-15B57A70-912C-41F0-B260-0332668B7B07Q34109691-FD42D755-D09D-49A3-9B52-3580B4E3E4B0Q34243127-0105FDD6-9F75-45BB-93A4-10B7ED4AD3F1Q34245828-59515A3A-8EF9-485B-B5ED-34912EABB4DFQ34315684-9243167E-761E-45A7-A962-06E209A30B76Q34480666-C5368F5F-EF71-49B5-93FA-F84AFAF231D8Q34592610-C2C80AA1-EF37-4071-B898-C128807B3162Q34680457-85ED9A59-EC22-417A-B3B4-B29E8F289E20Q34783850-7DB57862-3226-4D3C-9CD4-06060DDE0BDEQ34908845-0B643C84-FE9F-40C3-B980-253BF2D417C0Q35000330-DA676EF2-6FCD-4924-8717-504C987997CEQ35022847-7287A78B-F028-49D2-A299-C7E4DD92F900Q35082619-7BC0278A-F5CA-4BB9-AEAA-958A321BB10BQ35120828-665BC44D-C117-45DE-A017-E403C6ADC194Q35141461-032E58DE-CB6A-4CA0-BBC5-E41116B8A118Q35167133-0227953D-42FC-47D3-A428-0E2BF8E93A8EQ35195576-BA4F51E9-4E94-424F-A0C5-E9805061F61F
P2860
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@en
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@nl
type
label
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@en
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@nl
prefLabel
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@en
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@nl
P2093
P2860
P356
P1476
Estrogen receptor-positive, pr ...... sion and tamoxifen resistance.
@en
P2093
Adrian V Lee
C Kent Osborne
Grazia Arpino
Heidi Weiss
Rachel Schiff
Richard M Elledge
Sabino De Placido
P2860
P304
P356
10.1093/JNCI/DJI249
P407
P577
2005-09-01T00:00:00Z